Seven years ago, Cyberonics was all but dead, with an interesting technology and little else. Left at the altar when St. Jude refused to exercise an option to buy the company, Cyberonics faced the daunting task of getting FDA approval for a novel approach to epilepsy therapy and convincing a conservative customer group, neurologists, of the value of its vagus nerve stimuation (VNS) therapy. But Cyberonics was able to establish VNS in epilepsy and the company is now targeting depression, a market that could be as much as ten times larger than its first indication. And as Cyberonics' prospects brighten, the company now faces the challenge of keeping would-be acquirers at bay.
By David Cassak
October 16th, 2003, is a warm, sunny day in Houston, what passes for autumn in South Texas, and from his...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.